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The coronavirus SARS-CoV-2 has reached almost every corner of the globe. Trillions of dollars are being
invested in the COVID-19 pandemic response to support frontline clinical and public health efforts and
spur rapid advances in scientific research. Concurrently, we are in the grip of a pandemic of greater
longevity that receives scant public attention despite causing 4000 deaths each day [1]. It strikes
disproportionately at the poor, treatment is unsatisfactory, and there is no effective vaccine with lasting
immunity. This is tuberculosis (TB), another respiratory pathogen that has much in common with
COVID-19. In contrast to COVID-19, citizens of rich countries do not feel threatened by TB, which has
long been associated with poverty and is therefore not a strategic priority. The rise in isolationism,
nationalism, xenophobia, and racism has had negative impacts on health policy that have impaired global
and national responses to TB [2]. It is against these barriers that the global response to COVID-19 has
also been struggling. Worryingly, early models predict that the COVID-19 pandemic may drive an
additional 6.3 million TB cases and 1.3 million deaths by 2025 [3] and early data indicate interactions
between these diseases [4, 5]. Despite the political rhetoric suggesting that “we are all in this together”
when it comes to COVID-19, closer inspection through the lens of TB reminds us that when it comes to
benefitting from scientific advances to improve health, we are not all equal.
Rapid expansion and dissemination of COVID-19 clinical research
The number of clinical trials investigating COVID-19 registered with the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP) had reached over 4800 as of 5 August,
2020 [6]. Collaboration between institutions is encouraged over competition, and ethical approval
processes are taking days rather than months. Many publishing companies have made articles on
COVID-19 open-access or free of charge, and the use of preprints can further improve transparency and
encourage discourse between scientists and the public. These efforts prove that the research community
can respond quickly and that the layers of bureaucracy normally shrouding clinical research can be
reduced. Yet, there has been limited discourse about ensuring equity of access to future advances.
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Currently much of the focus of COVID-19 research is on treatment for hospitalised patients, often those
in intensive care, not in the community where most COVID-19 patients are found. Exceptions include the
UK PRINCIPLE (Platform randomised trial of interventions against COVID-19 in older people) trial,
which seeks to evaluate treatments that could prevent hospitalisation in people over 50 years of age [7].
Lessons can be learned from the decentralisation of TB care, which seeks to promote earlier diagnosis and
treatment to decrease transmission and reduce the need for hospital-based care [8]. Research focused on
the development and implementation of community-based strategies, including social distancing and the
use of facemasks [9], for COVID-19 prevention and mitigation is urgently needed, given that health
systems in many countries have become overwhelmed to the point of collapse.
Diagnostics
In contrast to TB, there has been rapid progress to develop and obtain emergency use authorisations for
COVID-19 tests. Yet, similarly to the challenges of interpreting immunological assays for latent TB
infection or understanding the negative predictive value of tests such as smear microscopy or urine
lipoarabinomannan for TB disease [10], COVID-19 testing has raised questions regarding the sensitivity
and duration of positivity of molecular tests and the relationship between positive serological testing and
lasting immunity [11]. New concepts have been proposed including “immunity passports”, which may be
issued to those with detectable antibodies; however, this could negatively impact equity by creating a tiered
society, and thus recommendations for serological test interpretation must be clear. While the ability to
perform COVID-19 testing using the Gene Xpert platform may facilitate scale-up of COVID-19 testing in
high TB incidence countries, challenges encountered during the widespread implementation of Xpert
MTB/RIF including gaps in linkage to care, monopolisation by a single diagnostic platform, and reliance
on donor support should inform COVID-19 testing strategies [12].
New drugs
Drug regulatory agencies such as the US Food and Drug Administration, European Medicines Agency, and
UK Medicines and Healthcare products Regulatory Agency have set up COVID-19 treatment acceleration
programmes to facilitate the navigation of administrative requirements and expedite review. In contrast,
years of TB research underfunding have stifled TB drug development. More than 50 years elapsed between
the development of the core drug regimen in the 1950s and the introduction of bedaquiline, the first new
antibiotic developed to treat TB in the 21st century [13]. TB treatment has remained lengthy, complex,
and toxic, particularly for people with drug-resistant TB [1].
Although regimens including new and repurposed drugs such as bedaquiline and linezolid are now
recommended by the WHO, most patients who would benefit from new TB treatments are not receiving
them due to prohibitive costs and delays in regulatory approvals [1, 14, 15]. Early indications that
remdesivir may be effective in COVID-19 immediately highlighted similar equity concerns regarding
treatment scale-up [16, 17], despite the substantial contribution of patients from low-resource settings to
the clinical trials that were vital to drug development and evaluation [18]. While efforts to ramp up
production were underway, Gilead donated its entire supply of remdesivir to the US government.
However, the lack of transparency regarding the initial distribution of the drug within the USA received
widespread criticism, particularly given its conspicuous absence in major safety net hospitals [19]. This is
an important reminder that the global impact of effective new drugs will depend heavily on the speed and
approach to scale-up drug production, as well as principles underpinning distribution, in the shifting
landscape of heavily affected countries. Voluntary licences with generic drug manufacturers in countries
like India may help. In contrast, data from the UK RECOVERY (Randomised Evaluation of COVID-19
Therapy) study indicate that a cheap and widely available drug, dexamethasone, decreases mortality in
COVID-19 patients requiring respiratory support [20]. This highlights the important benefit that
well-designed, timely clinical trials can provide to patients in both high- and low-income settings, if
scale-up is rapid.
Vaccines
Promising early data suggest that recently developed vaccines may induce protection against SARS-CoV-2 [21].
Oxford University has formed a collaboration with AstraZeneca for global development and distribution of
the University’s potential recombinant adenovirus vaccine, with both partners agreeing to operate on a
not-for-profit basis during the pandemic [22]. It remains to be seen how accelerated plans for vaccine
testing will be scaled up in low- and middle-income countries. We compare this to TB where there is just
one vaccine in clinical use, the bacille Calmette–Guérin (BCG) vaccine, developed in the 1920s and which
is of limited effectiveness, compared to the over 150 SARS-CoV-2 vaccines currently in development
including 21 in clinical evaluation [23]. Shortages of the BCG vaccine continue to occur [24] and,
ironically, media attention surrounding its potential role to prevent COVID-19 may further compromise
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supplies [25]. Vaccine implementation efforts will also need to address the vaccine hesitancy lobby, which
remains resolute despite the universal risks of COVID-19 [26].
Developing an explicit agenda to address research equity
Analyses from UK data demonstrate that COVID-19 mortality is disproportionately higher in Black, Asian
and Minority Ethnic groups, which is likely driven by unequal social determinants of health, including the
occupational risks of serving as essential workers [27]. While urgent efforts are needed to tackle structural
racism as a health issue, researchers must simultaneously ensure representation of affected communities in
study populations. We know that those living near university-affiliated hospitals are more likely to be
enrolled into clinical trials, leaving minorities, rural communities, and countries without links to
established academic institutions at risk of being left behind [28]. The WHO has taken positive action
through launching the SOLIDARITY trial which has over 90 countries participating, but more active steps
to include marginalised populations are needed [29]. Successful interventions should be produced at scale
and distributed according to need, not wealth.
Conclusions
The WHO’s Alma-Ata declaration in 1978 stated that gross health inequalities are unacceptable. The
COVID-19 pandemic emphasises the disproportionate burden of emerging threats faced by communities
already suffering from major health inequities. Despite efforts by the USA to withdraw funding from the
WHO, the need for a coordinated global public health response is more apparent than ever. Although
COVID-19 has captured public and political attention in a way that TB has consistently failed to achieve,
our experience with TB serves to remind us of the gaps in the research agenda that must be addressed to
ensure that scientific advances are equitably disseminated (table 1). Unfortunately, as in TB, mistrust of
governments and health systems is likely to compromise the COVID-19 response [30]. Consistent and
clear scientific and political communication with the public can help to ensure the success of public health
efforts. Interventions should not be executed in a one-size-fits-all manner, but should be adapted based on
community needs and seek to mitigate social injustices. The response to COVID-19 has shown us that
fast-track research, collaboration, data sharing, and rapid increases in funding to address global health
crises are possible. We argue that these innovations must also be made available to those working to defeat
TB and other public health threats, as part of long-term, sustainable strategies to ensure that all members
of the global community benefit from scientific advances. This will require strong political leadership, and
a commitment to the WHO’s stated goal of Health for All.
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